Published in J Hepatol on July 01, 2004
Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol (2013) 1.25
Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol (2010) 1.00
Hepatic encephalopathy. Saudi J Gastroenterol (2012) 0.96
Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol (2011) 0.94
Cirrhosis and its complications: evidence based treatment. World J Gastroenterol (2014) 0.93
Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res (2011) 0.93
Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag (2009) 0.90
Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y) (2011) 0.89
Acute esophageal variceal bleeding: Current strategies and new perspectives. World J Hepatol (2010) 0.87
The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol (2009) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol (2016) 0.85
A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol (2012) 0.85
Management of hepatic encephalopathy in the hospital. Mayo Clin Proc (2014) 0.85
Hepatic encephalopathy associated with cancer or anticancer therapy. Gastrointest Cancer Res (2013) 0.83
Management of hepatic encephalopathy. Int J Hepatol (2011) 0.82
Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Med Sci Monit (2011) 0.81
Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab (2010) 0.80
Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view. Hepatol Int (2014) 0.79
Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma? J Hepatol (2004) 0.79
Nutritional status and liver transplantation. J Clin Exp Hepatol (2012) 0.79
Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepat Med (2011) 0.78
Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract (2012) 0.78
Malnutrition in liver cirrhosis:the influence of protein and sodium. Middle East J Dig Dis (2013) 0.76
High Protein Diet and Huntington's Disease. PLoS One (2015) 0.76
Rifaximin in the treatment of hepatic encephalopathy. Hepat Med (2011) 0.76
Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy. Int J Mol Sci (2013) 0.76
Hepatic encephalopathy: An approach to its multiple pathophysiological features. World J Hepatol (2012) 0.76
Restricting protein intake not beneficial. Dtsch Arztebl Int (2012) 0.75
Medical Care of the Patient With Compensated Cirrhosis. Gastroenterol Hepatol (N Y) (2006) 0.75
Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. ISRN Hepatol (2014) 0.75
What improves minimal hepatic encephalopathy: probiotic yogurt, protein restriction or nonabsorbable disaccharides? Saudi J Gastroenterol (2012) 0.75
Hepatic encephalopathy: Ever closer to its big bang. World J Gastroenterol (2016) 0.75
Hepatobiliary quiz-7 (2013). J Clin Exp Hepatol (2013) 0.75
Managing complications in cirrhotic patients. United European Gastroenterol J (2015) 0.75
Management options in decompensated cirrhosis. Hepat Med (2015) 0.75
Nutrition therapy: Integral part of liver transplant care. World J Gastroenterol (2016) 0.75
Protein tolerance to standard and high protein meals in patients with liver cirrhosis. World J Hepatol (2017) 0.75
Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacology (2014) 0.75
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology (2010) 2.44
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol (2009) 2.39
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol (2013) 2.11
Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol (2003) 2.04
Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol (2005) 2.00
Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol (2010) 1.96
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology (2002) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol (2011) 1.80
Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl (2006) 1.77
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol (2009) 1.72
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol (2012) 1.71
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol (2005) 1.58
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood (2006) 1.57
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol (2004) 1.55
Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int (2009) 1.48
Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. Liver Int (2012) 1.46
High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res (2009) 1.39
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Multicenter, prospective, randomized, single-blind study comparing the efficacy and gastrointestinal complications of early jejunal feeding with early gastric feeding in critically ill patients. Crit Care Med (2002) 1.27
Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clin Gastroenterol Hepatol (2009) 1.24
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology (2012) 1.19
Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. Am J Gastroenterol (2011) 1.17
Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol (2010) 1.16
Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol (2008) 1.13
Sporadic cases of acute autochthonous hepatitis E in Spain. J Hepatol (2004) 1.11
Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. Hepatology (2004) 1.10
Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: Resolving the nitty-gritty. Hepatology (2014) 1.09
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology (2007) 1.07
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol (2005) 1.05
Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain. Clin Vaccine Immunol (2006) 1.03
Immunonutrition in the intensive care unit. A systematic review and consensus statement. Clin Nutr (2003) 1.03
1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis (2002) 1.00
Specific cleavage of hepatitis C virus RNA genome by human RNase P. J Biol Chem (2002) 1.00
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood (2010) 0.97
Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res (2011) 0.97
A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antiviral Res (2013) 0.96
Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J Clin Virol (2005) 0.94
Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J Virol (2005) 0.93
Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection? Liver Transpl (2010) 0.92
Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol (2002) 0.92
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS (2007) 0.92
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver Int (2012) 0.92
Neuropsychological abnormalities in cirrhosis include learning impairment. J Hepatol (2005) 0.92
Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation (2007) 0.91
Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol (2004) 0.91
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol (2005) 0.90
Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation (2007) 0.89
In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1. Cancer Immunol Immunother (2008) 0.89
Structural analysis of hepatitis C RNA genome using DNA microarrays. Nucleic Acids Res (2004) 0.88
Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology (2006) 0.87
Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screening clinic. Am J Cardiol (2009) 0.87
Prevalence of hepatitis E virus infection in children in the northeast of Spain. Clin Vaccine Immunol (2008) 0.87
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis (2009) 0.85
Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy. Dig Liver Dis (2011) 0.84
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol (2008) 0.84
HBV core region variability: effect of antiviral treatments on main epitopic regions. Antivir Ther (2011) 0.83
Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl (2002) 0.83
Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol (2008) 0.82
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. J Hepatol (2005) 0.82
1990-2010: two decades of interferon-based therapy. Clin Liver Dis (2011) 0.82
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res (2011) 0.82
Adefovir dipivoxil. Drugs Today (Barc) (2003) 0.82
Entecavir, FTC, L-FMAU, LdT and others. J Hepatol (2003) 0.82
Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. World J Gastroenterol (2012) 0.82
High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int (2010) 0.81
Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther (2006) 0.81
MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol (2013) 0.81
New therapeutic perspectives in HBV: when to stop NAs. Liver Int (2014) 0.81
Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. J Hepatol (2008) 0.81
Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues. J Med Virol (2007) 0.81
[Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)]. Gastroenterol Hepatol (2012) 0.81
Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection. Liver Int (2013) 0.80
Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology (2003) 0.80
Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology (2012) 0.79
Sexual transmission of hepatitis C virus from a patient with chronic disease to his sex partner after removal of an intrauterine device. Sex Transm Dis (2003) 0.79
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther (2008) 0.79
Drugs in development for hepatitis B. Drugs (2005) 0.79
Safety and metabolic tolerance of a concentrated long-chain triglyceride lipid emulsion in critically ill septic and trauma patients. JPEN J Parenter Enteral Nutr (2003) 0.79
Cancer vaccination: manipulation of immune responses at old age. Mech Ageing Dev (2008) 0.79
Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol (2012) 0.79
Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning. Eur J Gastroenterol Hepatol (2008) 0.78
Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. Expert Rev Gastroenterol Hepatol (2014) 0.78
Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. World J Gastroenterol (2013) 0.78
Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics (2005) 0.78
Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. J Clin Microbiol (2008) 0.77
Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? Eur J Gastroenterol Hepatol (2002) 0.77